Mark and Amy look at cagrilintide, a long-acting version of the fullness hormone amylin, developed mainly to pair with semaglutide as CagriSema. They go through what the phase 2 and phase 3 trials found, how it differs from GLP-1 drugs, and where it stands with regulators. The site rates the evidence 4 of 5.
What we covered
- What amylin is and why a once-weekly version exists
- Phase 2 (Lancet 2021): about -10.8% at 26 weeks vs -3.0% on placebo
- REDEFINE 1: cagrilintide alone about -11.5% at 68 weeks vs -3.0% on placebo
- CagriSema about -20.4% vs -14.9% for semaglutide alone over 68 weeks
- Not approved on its own; the combination is under FDA review, decision expected around late 2026
- WADA banned: yes
- Calculator arithmetic only: 10 mg vial plus 4 mL water is 2.5 mg/mL
Sources
- Cagrilintide: the weekly amylin analog behind CagriSema
- https://www.mypeps.info/peptides/cagrilintide
- https://www.mypeps.info/calculator
- https://www.mypeps.info/methodology
Free tools
- Peps calculator: https://www.mypeps.info/calculator
This is education, not medical advice.
Educational information, not medical advice. Mark and Amy are AI-generated voices; every episode is reviewed by our editor, Ryan E., MS.
#peptideresearch #clinicaltrials #sciencepodcast #healthliteracy #thepepsreport